BBNX (Beta Bionics) 1-Year Sharpe Ratio: 0.53 (As of Sep. 07, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

BBNX Beta Bionics Inc BBNX
13 GF Score
Price $19.42
! 3 Warning Signs
View Full Analysis

What is Beta Bionics 1-Year Sharpe Ratio?

Beta Bionics BBNX -2.51% 13 1-Year Sharpe Ratio is 0.53 as of Sep. 07, 2026. GuruFocus rates BBNX with a GF Score™ of 13/100. The stock has 3 warning signs investors should review.

The 1-Year Sharpe Ratio measures the additional return that an investor receives per unit of increase in risk over the past year. As of today (2026-09-07), Beta Bionics's 1-Year Sharpe Ratio is 0.53.

Beta Bionics  (NAS:BBNX) 1-Year Sharpe Ratio Explanation

The 1-Year Sharpe Ratio inidicates the risk-adjusted return of an investment over the past year. It is calculated as the annualized result of the average monthly excess return divided by its standard deviation over the past year. The monthly excess return is the monthly investment return minus the monthly risk-free rate (typically the 10-year Treasury Constant Maturity Rate). If the risk-free rate for a specific region is not available, U.S. data is used by default.

The greater a portfolio's Sharpe Ratio, the better its risk-adjusted performance. A negative Sharpe Ratio means the risk-free rate is greater than the portfolio’s historical or projected return, or else the portfolio's return is expected to be negative.

Beta Bionics 1-Year Sharpe Ratio Related Terms

BBNX vs CBLL, SIBN, INMD: 1-Year Sharpe Ratio Comparison

For the Medical Devices subindustry, Beta Bionics's 1-Year Sharpe Ratio, along with its competitors' market caps and 1-Year Sharpe Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Beta Bionics 1-Year Sharpe Ratio vs Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Beta Bionics's 1-Year Sharpe Ratio distribution charts can be found below:

* The bar in red indicates where Beta Bionics's 1-Year Sharpe Ratio falls into.


BBNX
13GF Score
Beta Bionics Inc BBNX
1-Year Sharpe Ratio is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Beta Bionics 1-Year Sharpe Ratio Calculation

The 1-Year Sharpe Ratio measures the performance of an investment such as a stock or portfolio compared to a risk-free asset. A stock / portfolio's 1-Year Sharpe Ratio can be calculated by dividing the difference between the one-year returns of the investment and the risk-free rate, by the standard deviation of the investment returns over one year.

Frequently Asked Questions Learn more about 1-Year Sharpe Ratio →
What does a 1-Year Sharpe Ratio of 0.53 mean?
Beta Bionics (BBNX) has a 1-Year Sharpe Ratio of 0.53 as of Sep. 07, 2026. 1-Year Sharpe Ratio measures the additional return that an investor receives per unit of increase in risk. View historical data for Beta Bionics and its competitors.
Is Beta Bionics' 1-Year Sharpe Ratio too high?
Beta Bionics' current 1-Year Sharpe Ratio is 0.53. Overall, Beta Bionics has a GF Score™ of 13/100, reflecting its overall financial health beyond just this single metric.
How does Beta Bionics' 1-Year Sharpe Ratio compare to CBLL and SIBN?
Beta Bionics' 1-Year Sharpe Ratio of 0.53 can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 1-Year Sharpe Ratio for a Medical Devices & Instruments company?
A good 1-Year Sharpe Ratio depends on the Medical Devices & Instruments industry context. However, 1-Year Sharpe Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 1-Year Sharpe Ratio mean?
A high 1-Year Sharpe Ratio can signal that a stock is expensive relative to its fundamentals. 1-Year Sharpe Ratio measures the additional return that an investor receives per unit of increase in risk. View historical data for Beta Bionics and its competitors. Beta Bionics's current 1-Year Sharpe Ratio is 0.53. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Beta Bionics stock overvalued right now?
Beta Bionics (BBNX) has a current 1-Year Sharpe Ratio of 0.53. The current 1-Year Sharpe Ratio is 0.53. Beta Bionics' overall GF Score™ is 13/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 1-Year Sharpe Ratio calculated?
1-Year Sharpe Ratio is calculated from a company's financial statements. For Beta Bionics (BBNX), the current 1-Year Sharpe Ratio is 0.53 as of Sep. 07, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Beta Bionics Business Description

Address 11 Hughes, Irvine, CA, USA, 92618
Beta Bionics Inc is a commercial-stage medical device company engaged in the design, development, and commercialization of solutions to improve the health and quality of life of insulin-requiring people with diabetes (PWD) by utilizing adaptive closed-loop algorithms to simplify and improve the treatment of their disease. The company's product includes the iLet Bionic Pancreas (iLet). The company operates as a single segment, focused on the development, manufacture, and sale of the iLet.
13GF Score

Get the complete analysis for BBNX

1-Year Sharpe Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$19.42
Price